GlassScriptPhysician profile
Wali A Danesh
NPI 1598789463
$1,004.13
in general payments reported to CMS, 2019-2025
14 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.72 · 2020: $97.79 · 2021: $19.67 · 2022: $36.63 · 2023: $283 · 2024: $151 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $211.79 | 2023-2025 | Airsupra, Breztri, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.41 | 2019-2025 | Jardiance |
| Abbvie INC. | $184.81 | 2022-2023 | Ubrelvy |
| Lilly USA, LLC | $117.55 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $70.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $46.30 | 2019-2025 | |
| Novo Nordisk INC | $33.71 | 2022-2025 | Ozempic |
| Glaxosmithkline, LLC. | $32.59 | 2024-2025 | Trelegy Ellipta |
| Medtronic, INC. | $26.18 | 2023 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $22.45 | 2025 | Voquezna |
| Halozyme INC | $18.12 | 2023 | |
| Bausch Health US, LLC | $17.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.53 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $12.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wali Danesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.